title: Intermittent naloxone attenuates the development of physical dependence on methadone in rhesus monkeys.
abstract: Rhesus monkeys that received 15 daily injections of methadone (2 mg/kg i.m.) exhibited a characteristic opiate withdrawal syndrome after injection of naloxone (0.5 mg/kg i.m.) on the 16th day. In comparison, injection of naloxone (0.5 mg/kg i.m.) once every 2 days during a similar 15 day methadone treatment period in these same monkeys significantly attenuated the severity of the opiate withdrawal syndrome exhibited after naloxone injection on the 16th day. Each naloxone administration during the 15 day methadone treatment period elicited an opiate withdrawal syndrome that did not significantly differ on each of the 7 days it was given and was less severe than the syndrome precipitated by naloxone following 15 days of methadone without intermittent naloxone. The lack of increments in the withdrawal response to the seven naloxone injections during the 15 days of methadone treatment and the attenuation of the withdrawal response to naloxone on day 16 after intermittent naloxone administration during the 15 day methadone treatment period support the hypothesis that naloxone modifies opiate receptor mechanisms so that they revert to an agonist-naive state following antagonist exposure. These findings suggest that various agonist and antagonist opiate drug combinations or mixed agonist-antagonist drug could be clinically useful in the management of situations where physical dependence on opiates is a problem.
authors.affiliation: Abraham Ribicoff Research Facilities, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06508.
authors.forename: J H
authors.initials: JH
authors.lastname: Krystal
authors.forename: M W
authors.initials: MW
authors.lastname: Walker
authors.forename: G R
authors.initials: GR
authors.lastname: Heninger
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D005260:Female; D008253:Macaca mulatta; D008297:Male; D008691:Methadone / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology*; D011957:Receptors, Opioid / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000139:chemically induced / Q000523:psychology; D019966:Substance-Related Disorders / Q000503:physiopathology*; D013997:Time Factors
chemical_list: D011957:Receptors, Opioid; D009270:Naloxone; D008691:Methadone